7 registrations that name DHEA as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 7 registrations
Status
Phase
4US sites across 4 states
1
2 to 4
5 to 19
20 or more
All 7 registrations
RecruitingNCT07574216
VEDA Study (DHEA vs Estradiol)
No phase
University of Arizona
About 324 people
Started Aug 4, 2026
In plain words A study of DHEA in female participants 40 to 90, run by University of Arizona. It plans to enroll about 324 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 40 to 90; healthy volunteers accepted. Conditions: Post-menopause; Pre-menopause; Sexual Function; Menopause; Vaginal Dryness; Painful Intercourse.
Peri- or post-menopausal status
Presence of any genitourinary or vaginal symptom (e.g., dryness, itching, discomfort, dyspareunia)
Willingness and ability to use vaginal therapy
Ability to provide informed consent
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
DHEA ovals; Estradiol 0.01% Vag Cream
Registered summary
This study is being done to compare two vaginal treatments, vaginal estrogen and vaginal DHEA, that are used to treat vaginal and urinary symptoms related to menopause. These symptoms may include vaginal dryness, discomfort, painful intercourse, or urinary problems and can affect quality of life and sexual health. Women who choose to participate will be randomly assigned to use one of the two treatments for a set period of time. Participants will complete questionnaires about their symptoms and sexual health and have simple vaginal testing at the beginning and end of the study. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT03228732
The Effects of Fluoxetine and/or DHEA
Early phase 1
University of Maryland, Baltimore
About 60 people
Started Dec 19, 2017
In plain words An early phase 1 study of DHEA in people 18 to 50, run by University of Maryland, Baltimore. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 50. Conditions: Type 1 Diabetes Mellitus.
(1) To determine how the Selective Serotonin Reuptake Inhibitor (SSRI), fluoxetine (Prozac), an antidepressant often used to treat depression, stimulates the participant's body's ability to defend against low blood sugar (hypoglycemia). (2) To learn how a hormone, dehydroepiandrosterone (DHEA), stimulates the participant's body's ability to defend itself from low blood sugar (hypoglycemia). DHEA is a hormone produced naturally in the human body. However, it can be manufactured and is sold as an over-the-counter dietary supplement. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07407647
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Phase 2
Ohio State University Comprehensive Cancer Center
About 25 people
Started Mar 12, 2026
In plain words A Phase 2 study of DHEA in female participants 50 and older, run by Ohio State University Comprehensive Cancer Center. It plans to enroll about 25 people at 1 US site.
Any patient with anal, rectal, cervical, vaginal, or vulvar cancer receiving external beam radiation alone, or both external beam radiation and brachytherapy with curative intent (Participants will be consented and enrolled prior to…
Concurrent or prior chemotherapy is allowed
Any prior gynecologic surgery is permitted
Rectal surgery, including lower anterior resection and abdominoperineal resection, is permitted
1 more inclusion criterion and the exclusion criteria are on the listing.
This phase II trial tests the feasibility and side effects of vaginal DHEA to improve vaginal health after radiation for women with gynecologic, anal or rectal cancer. Treatment of cancers with radiation to the abdomen can influence the vaginal microbiome (any bacteria, virus, or other organisms found in the vagina). Both menopause and radiation cause a decrease in lubrication and elasticity of the vagina and symptoms including vaginal dryness, vaginal burning and itching, vaginal bleeding, pain or burning during urination, and pain during sexual intercourse. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07843927
Dehydroepiandrosterone (DHEA) as Augmentation of Standard Antidepressants in Treatment-resistant Depression.
Phase 3
Charite University, Berlin, Germany
About 320 people
Started Jun 22, 2026
In plain words A Phase 3 study of DHEA in people 18 to 75, run by Charite University, Berlin, Germany. It plans to enroll about 320 people at 9 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Treatment Resistant Depression (TRD).
Patient provided written informed consent
The patients is aged between 18 and 75 years (≥ 18 and ≤ 75)
The patient has an episode of major depression according to DSM 5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edi-tion)
The patient has treatment-resistant depression (TRD), defined as non-response to at least one 4-week antidepressant treatment trial (including the current treatment) in the index episode (correspond-ing to level 1 resistance to treatment…
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Dehydroepiandrosterone (DHEA); Placebo
Registered summary
Major depressive disorder (MDD) is a major contributor to impaired health worldwide. Initial antidepressant treatment of MDD does not lead to response in up to 50 % of patients. TRD (Treatment Resistant Depression) is associated with increased rates of recurrence, mortality as well as increased treating costs compared to MDD. Treatment op-tions for TRD remain limited with lithium, quetiapine and esketamine being the only recommended and approved augmentation strategies in the EU. The full summary is on the listing.
Where, as registered
No US site; Germany (9).
RecruitingNCT07323329
Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization
Phase 2 and 3
Beni-Suef University
About 165 people
Started Oct 10, 2025
In plain words A Phase 2 and 3 study of DHEA in female participants 18 to 35, run by Beni-Suef University. It plans to enroll about 165 people at 1 site, none in the US.
Advanced maternal age (>40 years) or any other risk factor for Poor Ovarian Response (POR).
≤3 oocytes with a conventional stimulation protocol).
An abnormal ovarian reserve test \[i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng/ml\].
The exclusion criteria are on the listing.
What it tests, as registered
Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day.; DHEA plus folic acid 400mcg per day; control group
Registered summary
The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder. The main question it aims to answer is: Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT05935761
Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial
Phase 2
VA Office of Research and Development
About 108 people
Starts Dec 1, 2026 (estimated)
In plain words A Phase 2 study of DHEA in people 18 to 65, run by VA Office of Research and Development. It plans to enroll about 108 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Chronic Low Back Pain.
Veterans with chronic low back pain
Based on medical history and medical records, have low back pain (Thoracic Vertebrae 6 or below) present on most days for the preceding 6 months or longer, and fulfill all disease diagnostic criteria (please see disease diagnostic criteria…
Have a weekly mean of 24-hour average pain score 4 at baseline
Negative pregnancy test if female. Sexually active subjects are required to use a medically acceptable form of birth control if they are of childbearing potential and could become pregnant during the study.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Pregnenolone; DHEA; Placebo
Registered summary
Chronic pain symptoms are very common among U.S. Military Veterans and have a profound negative impact on mental health symptoms and quality of life, in addition to increasing risk for suicidal ideation and suicidal behaviors. There are currently extremely few safe and effective pharmacological treatments for chronic pain disorders, and the clinical need to develop new therapeutics for pain has never been more urgent. Fueled by the worsening opioid crisis and further exacerbated by the COVID-19 pandemic, opioid and other drug overdose deaths have climbed to staggeringly high levels. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT06611514
Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer
Phase 3
European Institute of Oncology
About 95 people
Starts Dec 1, 2024 (estimated)
In plain words A Phase 3 study of DHEA in female participants 18 and older, run by European Institute of Oncology. It plans to enroll about 95 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Women With Breast Cancer.
Histologically confirmed breast cancer, completely excised
Natural or iatrogenic menopausal status
No evidence of distant metastasis
Self-identified moderate to severe symptoms of genitourinary syndrome
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Prasterone (DHEA)
Registered summary
The goal of this interventional study is to evaluate the effect of Intravaginal Prasterone for the treatment of moderate to severe symptoms of genitourinary syndrome (GSM) due to natural, surgical or treatment-induced menopause and the effect on the quality of life, including sexual function and mood well-being, in women with Breast Cancer. A sample size of 95 patients will be needed to show that the proportion of women showing symptom improvement is greater than 50%. Subjects will be followed up at four weeks and twelve weeks of treatment. The full summary is on the listing.